These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7046901)

  • 1. The usefulness of the Lukes-Collins classification in identifying subsets of diffuse histiocytic lymphoma responsive to chemotherapy.
    Newcomer LN; Nerenberg MI; Cadman EC; Waldron JA; Farber LR; Bertino JR
    Cancer; 1982 Aug; 50(3):439-43. PubMed ID: 7046901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A follow-up of a randomized study comparing two chemotherapy treatments for advanced diffuse histiocytic lymphoma.
    Todd M; Cadman E; Spiro P; Bertino J; Farber L; Waldron J; Fischer D
    J Clin Oncol; 1984 Sep; 2(9):986-93. PubMed ID: 6206207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
    Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
    Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical usefulness and reproducibility of histologic subclassification of advanced diffuse histiocytic lymphoma.
    Armitage JO; Dick FR; Platz CE; Corder MP; Leimert JT
    Am J Med; 1979 Dec; 67(6):929-34. PubMed ID: 391039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A morphologic study of childhood lymphoma of the diffuse "histiocytic" type. The Pediatric Oncology Group experience.
    Nathwani BN; Griffith RC; Kelly DR; Shuster JJ; Hvizdala E; Sullivan MP; Murphy SB; Berard CW
    Cancer; 1987 Mar; 59(6):1138-42. PubMed ID: 3545429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized study comparing doxorubicin, cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (ACOMLA) with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin (CHOP-B) in the treatment of diffuse histiocytic lymphoma.
    Newcomer LN; Cadman EC; Nerenberg MI; Chen M; Bertino JR; Farber LR; Prosnitz LR
    Cancer Treat Rep; 1982 Jun; 66(6):1279-84. PubMed ID: 6177407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of the Lukes and Collins classification in patient treated with COMLA.
    Sweet DL; Collins RD; Stein RS; Ultmann JE
    Cancer Treat Rep; 1982 May; 66(5):1107-11. PubMed ID: 7044531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Rappaport classification of non-Hodgkin's lymphomas: a closer look using other proposed classifications.
    Garvin AJ; Simon R; Young RC; DeVita VT; Berard CW
    Semin Oncol; 1980 Sep; 7(3):234-43. PubMed ID: 6998002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP).
    Armitage JO; Dick FR; Corder MP; Garneau SC; Platz CE; Slymen DJ
    Cancer; 1982 Nov; 50(9):1695-702. PubMed ID: 6749279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneity of response and survival in diffuse histiocytic lymphoma after BACOP therapy (bleomycin, doxorubicin, cyclophosphamide, vincristine, prednisone).
    Levine AM; Goldstein M; Meyer PR; Forman SJ; Parker JW; Paganini-Hill A; Lukes RJ; Feinstein DI
    Hematol Oncol; 1985; 3(2):87-98. PubMed ID: 2410348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose ACOP-B and VABE: weekly chemotherapy for elderly patients with advanced-stage diffuse large-cell lymphoma.
    O'Reilly SE; Klimo P; Connors JM
    J Clin Oncol; 1991 May; 9(5):741-7. PubMed ID: 1707954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential cyclophosphamide-prednisone and vincristine-bleomycin (CPOB). An effective, schedule-dependent treatment for advanced diffuse histiocytic lymphoma.
    Johnson GJ; Costello WG; Oken MM; Sponzo RW; Barnes JM; Ezdinli EZ; Bennett JM; Silverstein MN; Glick JH; Berard CW
    Cancer; 1983 Oct; 52(7):1133-41. PubMed ID: 6192894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of morphologic subdivision in diffuse large cell lymphoma.
    Kwak LW; Wilson M; Weiss LM; Horning SJ; Warnke RA; Dorfman RF
    Cancer; 1991 Nov; 68(9):1988-93. PubMed ID: 1913547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An autopsy study of histologic progression in non-Hodgkin's lymphomas. 192 cases from the National Cancer Institute.
    Garvin AJ; Simon RM; Osborne CK; Merrill J; Young RC; Berard CW
    Cancer; 1983 Aug; 52(3):393-8. PubMed ID: 6344979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical significance of the morphological subdivision of diffuse "histiocytic" lymphoma: a study of 162 patients treated by the Southwest Oncology Group.
    Nathwani BN; Dixon DO; Jones SE; Hartsock RJ; Rebuck JW; Byrne GE; Sheehan WW; Kim H; Coltman CA; Rappaport H
    Blood; 1982 Nov; 60(5):1068-74. PubMed ID: 6751435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized comparison of methotrexate dose and the addition of bleomycin to CHOP therapy for diffuse large cell lymphoma and other non-Hodgkin's lymphomas. Cancer and Leukemia Group B study 7851.
    Gottlieb AJ; Anderson JR; Ginsberg SJ; Bloomfield CD; Norton L; Barcos M; Peterson BA; Nissen N; Henderson ES; Holland JF
    Cancer; 1990 Nov; 66(9):1888-96. PubMed ID: 1699653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late relapse in patients with diffuse large-cell lymphoma treated with MACOP-B.
    Lee AY; Connors JM; Klimo P; O'Reilly SE; Gascoyne RD
    J Clin Oncol; 1997 May; 15(5):1745-53. PubMed ID: 9164181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of diffuse histiocytic lymphoma (DHL) with COMLA (cyclophosphamide, oncovin, methotrexate, leucovorin, cytosine arabinoside): a 10-year experience in a single institution.
    Gaynor ER; Ultmann JE; Golomb HM; Sweet DL
    J Clin Oncol; 1985 Dec; 3(12):1596-604. PubMed ID: 3877790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nodular histiocytic lymphoma: factors influencing prognosis and implications for aggressive chemotherapy.
    Glick JH; McFadden E; Costello W; Ezdinli E; Berard CW; Bennett JM
    Cancer; 1982 Mar; 49(5):840-5. PubMed ID: 7037153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Curative radiotherapy for localized diffuse histiocytic lymphoma.
    Levitt SH; Bloomfield CD; Frizzera G; Lee CK
    Cancer Treat Rep; 1980 Jan; 64(1):175-7. PubMed ID: 6991104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.